Hainan Bright Future Pharmaceutical Co. Ltd.

Primary objective: This study used lamotrigine tablets (specification: 50 mg) developed by Aome Pharmaceuticals (Hainan) Co., Ltd. as the test preparation. According to the relevant provisions of bioequivalence studies, lamotrigine tablets (specification: 50 mg, trade name: LAMICTAL®) owned by The Wellcome Foundation Limited and produced by DELPHARM POZNAN SPOLKA AKCYJNA were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary objective: To observe the safety of the test preparation lamotrigine tablets and the reference preparation lamotrigine tablets (trade name: LAMICTAL®) in healthy subjects.

Main purpose: This study uses the oseltamivir phosphate dry suspension (specification: 6 mg/mL) developed by Aome Pharmaceutical (Hainan) Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, the oseltamivir phosphate dry suspension (specification: 6 mg/mL, trade name: Tamiflu®) certified by Roche Registration GmbH and produced by Roche Pharma AG is used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: To observe the safety of the test preparation oseltamivir phosphate dry suspension and the reference preparation oseltamivir phosphate dry suspension (trade name: Tamiflu®) in healthy subjects.

Main purpose of study: According to the relevant provisions of bioequivalence test, potassium chloride sustained-release tablets (trade name: KLOR-CON®, specification: 8mEq) of UPSHER-SMITH LABORATORIES, LLC as the licensee were selected as the reference preparation, and the test preparation potassium chloride sustained-release tablets (specification: 8mEq) produced and provided by Aome Pharmaceutical (Hainan) Co., Ltd. were subjected to fasting human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary purpose of study: To observe the safety of oral administration of the test preparation potassium chloride sustained-release tablets (specification: 8mEq) and the reference preparation potassium chloride sustained-release tablets (trade name: KLOR-CON®, specification: 8mEq) by healthy volunteers.